TMS vs ECT: Effectiveness, Memory and Who Each Suits

ECT is more effective than TMS overall, especially for psychotic depression, while TMS is far less demanding: no anesthesia, no induced seizure and no reliable evidence of memory side effects. In the largest head-to-head meta-analysis, remission was 52.9% with ECT vs 33.6% with high-frequency rTMS, but in non-psychotic depression the two performed similarly. The honest summary is that ECT is the stronger treatment and TMS is the gentler one, and the right choice depends on how severe and urgent the depression is.

For most people with non-psychotic, treatment-resistant depression who are not in immediate danger, guidelines suggest trying TMS before ECT. For psychotic depression, catatonia, severe suicidality or depression that is life-threatening, ECT is the treatment with the strongest evidence and is usually preferred.

TMS and ECT side by side

Those response ranges come from guideline summaries of different populations. They show the general gap, not what either treatment would do for one person.

The head-to-head evidence

Only a handful of randomized trials have compared the two directly, and they are small and short-term.

• Berlim and colleagues (2013) pooled 7 trials with 294 patients. After an average of 15.2 rTMS and 8.2 ECT sessions, remission was 33.6% with rTMS vs 52% with ECT, a number needed to treat of 6 in favor of ECT. Dropout did not differ.
• Ren and colleagues (2014) pooled 9 trials with 425 patients. ECT beat rTMS for response (64.4% vs 48.7%) and remission (52.9% vs 33.6%). The advantage was "more apparent in those with psychotic depression," while rTMS was as effective as ECT in non-psychotic depression. There were insufficient data on medium- or long-term efficacy.
• A 2025 network meta-analysis of 35 trials in more advanced treatment-resistant depression found no significant difference in response, remission or tolerability among ECT, rTMS and IV ketamine, but rated confidence in that evidence as very low.

These analyses partly disagree, and all are small. The fact-checked reading is that ECT is more effective overall, especially in psychotic depression; it is not accurate to say that TMS is as effective as ECT. Both meta-analyses compared ECT with conventional high-frequency rTMS, not with theta-burst or accelerated TMS protocols; no head-to-head comparison of those with ECT appears in the sources reviewed for this guide.

How strong ECT is on its own

ECT's reputation rests on decades of data. A 2003 Lancet meta-analysis found real ECT superior to simulated ECT and to medication, and bilateral superior to unilateral placement. In the CORE cohort of 253 patients given bilateral ECT three times a week, 75% remitted, and 65% had remitted by the tenth treatment, around weeks 3 to 4. That speed is one reason ECT is used when depression is dangerous.

TMS results are more modest in controlled trials. In sham-controlled studies, active TMS typically improves remission rates by about 9 to 18 percentage points over sham, and sham itself produces substantial improvement. Higher open-label figures are not comparable to these trial numbers. How to read TMS success rates is covered in response vs remission.

Memory and cognition

This is the main reason many people prefer TMS. In the NeuroStar development program, cognitive function did not change, and a review of 31 randomized trials of prefrontal rTMS found no reliable evidence of cognitive side effects. A plain-language explanation is on Mind Body Seven: TMS and memory.

ECT's cognitive effects are real but need precise description:

• On standard neuropsychological tests, a meta-analysis of 84 studies found that cognitive problems were mainly limited to the first 3 days after treatment, with some abilities above baseline by 15 days. It did not assess memory for past personal events.
• In a study of 347 patients at 7 New York City-area facilities, adverse cognitive effects were still detectable 6 months after the acute course. Bilateral ECT caused more severe and persistent retrograde amnesia than right unilateral ECT, and older sine-wave stimulation was worse still.
• In head-to-head trials, three studies suggested that visual memory and verbal fluency were more impaired with ECT than with rTMS; long-term cognitive comparisons are lacking.
• In the ELEKT-D trial, delayed-recall T-scores fell by 9.7 points with ECT vs 0.9 with ketamine at 3 weeks, with gradual recovery during follow-up.

Because electrode placement and stimulus type change the risk, with bilateral placement and older sine-wave stimulation causing more persistent deficits, the technique matters as much as the decision to have ECT. A psychiatrist recommending ECT should explain which technique will be used and how memory will be monitored during the course.

When ECT is the better choice

Guidelines are consistent that ECT should come first in several situations:

• Psychotic depression. ECT's advantage over rTMS is concentrated here, and the 2018 TMS consensus advises that people with psychotic symptoms be considered for other treatments with established efficacy, ECT being the example.
• Acute suicidal risk or depression that is life-threatening, for example from not eating or drinking. The VA/DoD guideline gives ECT a "strong for" recommendation in severe depression with catatonia, psychotic features or severe suicidality.
• Catatonia, for the same reason.
• A strong past response to ECT, or when a fast response is needed and TMS would take weeks.

TMS is not a crisis treatment. The research on rapid relief of suicidal thoughts is summarized in TMS and suicidal thoughts. If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

When TMS is the sensible first step

For non-psychotic depression that has not responded to medication, CANMAT 2023 says that, except in emergent situations, rTMS should generally be considered before ECT because it is less invasive. That fits people who:

• are not in immediate danger and can wait several weeks for a response;
• are worried about memory, for example because of demanding work or study;
• cannot have, or prefer to avoid, repeated general anesthesia;
• need to keep driving and working during treatment.

Choosing TMS first does not close the door on ECT. If TMS does not work, ECT remains available, and some people move from ECT to TMS: New York Medicare allows rTMS as a less invasive option for a patient currently receiving ECT. The treatment-resistant depression options compared page also covers esketamine and ketamine-assisted treatment; ketamine was non-inferior to ECT for non-psychotic treatment-resistant depression in the ELEKT-D trial.

Safety beyond memory

TMS side effects are usually limited to scalp discomfort and headache, and its most serious risk, an unintended seizure, is rare, at 0.71 per 1,000 patients in a large survey of Clinical TMS Society members. The details are in TMS safety and seizure risk. ECT involves general anesthesia at every session, which brings its own medical screening and recovery time. Because of the anesthesia, someone else needs to take the patient home after each ECT session, whereas TMS patients usually return to normal activities straight away.

Questions that usually decide it

In practice, the choice between TMS and ECT comes down to a few questions a psychiatrist will work through with the patient and, often, family:

1. How dangerous is the depression right now? Active suicidal planning, not eating or drinking, or catatonia point toward ECT, often in a hospital setting.
2. Are there psychotic symptoms, such as delusions of guilt or ruin, or hallucinations? If so, ECT has the clearer evidence.
3. How many treatments have already failed, and what kind? Someone who has not yet tried neuromodulation is usually a good candidate for TMS first; someone who has failed several strong options may be better served by ECT sooner.
4. How much would temporary memory problems cost? For a student near exams or someone in a cognitively demanding job, TMS's cognitive profile carries real weight.
5. Can the schedule be managed? TMS needs a daily visit for several weeks; ECT needs fewer visits but anesthesia recovery and an escort each time.
6. What has worked before? A past good response to either treatment is a strong reason to use it again.

Neither choice is permanent. Many people start with TMS and keep ECT in reserve, and the decision can be revisited if the clinical picture changes.

After either treatment: relapse

Neither treatment ends the risk of depression returning. After ECT, CANMAT 2023 notes recurrence in 60% to 80% of patients at 6 months, and in the CORE continuation trial relapse was 37.1% with continuation ECT and 31.6% with lithium plus nortriptyline. After TMS, pooled data show about half of responders still responding at 6 months and a little under half at 12 months. Both call for a plan for what comes next; see how long TMS results last.

The TMS therapy page explains how evaluation works, and the TMS guide collects the related evidence.

Frequently asked questions

Is TMS as effective as ECT?

No. In meta-analyses of head-to-head trials, ECT produced higher remission rates overall. The gap was concentrated in psychotic depression; in non-psychotic depression one analysis found the two similar.

Does TMS cause memory loss like ECT?

TMS has not shown reliable cognitive side effects in randomized trials. ECT commonly causes short-term memory problems, and some people have lasting gaps in memory for past events, more often with bilateral electrode placement.

Can I have TMS if ECT did not work for me?

Yes, TMS can be considered, though people whose depression did not respond to ECT may be harder to treat with any method. Your psychiatrist will review what was tried and how.

Does ECT require anesthesia?

Yes. Each ECT session is done under general anesthesia, so someone must take you home afterward. TMS needs no anesthesia, and most people drive themselves.

Which works faster?

ECT usually does. In one large cohort, about two-thirds of patients had remitted by the tenth treatment, around weeks 3 to 4. Standard TMS takes about 6 weeks, though accelerated protocols are shorter.

Sources

1. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. Depression and Anxiety, 2013. pubmed.ncbi.nlm.nih.gov
2. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014. pubmed.ncbi.nlm.nih.gov
3. Comparative efficacy and safety of intravenous racemic ketamine, repetitive transcranial magnetic stimulation and electroconvulsive therapy for Stage 2 or higher treatment-resistant depression: A systematic review and network meta-analysis. PCN Reports, 2025. europepmc.org
4. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. The Lancet, 2003. pubmed.ncbi.nlm.nih.gov
5. Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. Journal of Clinical Psychiatry, 2004. pubmed.ncbi.nlm.nih.gov
6. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Archives of General Psychiatry, 2006. pmc.ncbi.nlm.nih.gov
7. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology, 2007. pubmed.ncbi.nlm.nih.gov
8. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biological Psychiatry, 2010. pubmed.ncbi.nlm.nih.gov
9. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine, 2023. pubmed.ncbi.nlm.nih.gov
10. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults. Canadian Journal of Psychiatry, 2024. pmc.ncbi.nlm.nih.gov
11. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. Department of Veterans Affairs / Department of Defense, 2022. healthquality.va.gov
12. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. Journal of Clinical Psychiatry, 2018. pmc.ncbi.nlm.nih.gov
13. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. American Psychiatric Association, 2010. psychiatryonline.org
14. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology, 2021. europepmc.org
15. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. Journal of Clinical Psychiatry, 2008. europepmc.org
16. Seizure risk with repetitive TMS: Survey results from over a half-million treatment sessions. Brain Stimulation, 2021. europepmc.org
17. Durability of antidepressant response to repetitive transcranial magnetic stimulation: Systematic review and meta-analysis. Brain Stimulation, 2019. pubmed.ncbi.nlm.nih.gov
18. FDA 510(k) K231926 summary (NeuroStar Advanced Therapy System). U.S. FDA, 2024. accessdata.fda.gov
19. LCD L33398 Transcranial Magnetic Stimulation (version 40). CMS Medicare Coverage Database (Wellpoint Federal), 2026. cms.gov

Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.